Comparative Genomic Hybridization

Infer relative genomic copy-number gains and losses by competitively hybridizing differently labeled test and reference DNA and mapping their normalized signal ratio by locus.

Version

v1 · 2026-08-30 · History

Domain-specific #

1512

Origin domain

cytogenetics

Subdomain

genome-wide copy-number analysis

Aliases

CGH, Chromosomal CGH, Comparative genome hybridization

Core Idea

Comparative genomic hybridization (CGH) is a molecular-cytogenetic measurement architecture for detecting relative DNA copy-number gains and losses across a genome. Genomic DNA from a test sample and a reference sample is labeled with distinguishable fluorophores, mixed, and competitively hybridized to a common locus-ordered substrate. The normalized test-to-reference signal ratio is mapped by genomic position; departures from the balanced ratio indicate relative dosage differences.^[1][2]

Conventional CGH uses normal metaphase chromosomes as the substrate. Array CGH replaces chromosomes with mapped DNA probes, raising and regularizing resolution while retaining the same comparative-ratio principle.^[3]

The abstraction is the end-to-end comparator: test and reference genomes, differential labeling, common competitive hybridization, locus-resolved ratio, normalization and segmentation, and copy-number interpretation. It detects imbalance, not every kind of genomic variation.

Structural Signature

The recognition roles are:

1. Test DNA: genomic material whose relative dosage is unknown.
2. Reference DNA: a comparator with an explicitly characterized or assumed copy-number baseline.
3. Differential labels: test and reference can be separately measured after co-hybridization.
4. Common mixture: labeled samples compete under the same hybridization conditions.
5. Ordered substrate: metaphase chromosomes or mapped genomic probes locate signals.
6. Hybridization: complementary DNA binding converts abundance into fluorescence intensity.
7. Local signal pair: test and reference intensities are observed for each chromosome region or probe.
8. Normalization: systematic dye, amount, background, and global-intensity effects are controlled.
9. Ratio profile: often a log2 test/reference ratio is formed by genomic position.
10. Segmentation or thresholding: neighboring measurements are combined into candidate copy-number regions.
11. Relative interpretation: elevated ratio indicates test gain or reference loss; depressed ratio indicates test loss or reference gain.
12. Resolution and sensitivity: probe spacing, substrate, DNA quality, noise, mosaic fraction, and analysis pipeline bound detection.

The invariant is: relative genomic dosage is inferred from locus-specific competition between differently labeled test and reference DNA on one shared hybridization substrate.

What It Is Not

It is not conventional karyotyping. Banding observes chromosome morphology in cells; CGH derives a genome-wide dosage profile from extracted DNA.

It is not FISH to one or a few targeted loci, although conventional CGH uses fluorescence in situ hybridization chemistry.

It is not radiation hybrid mapping, which orders markers through retention patterns in hybrid cell panels.

It is not sequencing and does not generally identify single-nucleotide variants or small sequence substitutions.

It is not a complete rearrangement assay. Balanced translocations and inversions preserve dosage and are ordinarily invisible unless a breakpoint disrupts a measured probe or creates associated imbalance.

It is not absolute copy number without assumptions. The primary observation is test relative to reference and ploidy baseline.

It is not SNP genotyping. Standard CGH intensity alone lacks allele-specific information needed for copy-neutral loss of heterozygosity.

Scope of Application

CGH recurs in cancer cytogenetics, tumor evolution, constitutional copy-number analysis, developmental-disorder investigation, prenatal or postnatal diagnostics, model-organism genomics, and research screening for deletions and amplifications.^[1][4]

Conventional chromosomal CGH and array CGH are variants of the same abstraction. Their substrates, resolution, dynamic range, DNA requirements, and processing differ, but each compares two genomic samples by competitive hybridization and spatial signal ratio.

Clinical use requires validated platforms, quality controls, reference populations, interpretation standards, and confirmatory or orthogonal tests where appropriate. This node describes the measurement architecture, not a stand-alone medical recommendation.

Clarity

Recognition begins with two genomic DNA inputs and different labels. If a single sample is hybridized without a comparative reference signal, the assay is not CGH in this exact sense. Both samples must address the same ordered loci under comparable conditions.

For locus \(i\), a common summary is

\[ r_i=\log_2\frac{I_{T,i}}{I_{R,i}}, \]

after background correction and normalization. A balanced diploid test against diploid reference tends toward zero. A positive segment suggests relative test gain; a negative segment suggests relative loss. Thresholds are empirical and platform-specific.

Interpretations must preserve relativity. Tumor purity, aneuploid baseline, polyploidy, reference variation, mosaicism, and repetitive sequence can move or dilute ratios. Dye-swap or other controls can expose label bias.

Manages Complexity

CGH converts millions or billions of genomic bases into a spatial dosage profile. Instead of selecting one suspected locus at a time, it surveys the genome and routes anomalous regions to focused interpretation.

Competitive co-hybridization controls many environmental variables because test and reference experience the same substrate and reaction. Taking their ratio cancels shared multiplicative effects more effectively than comparing unrelated absolute signals.

Array CGH separates physical resolution from microscope banding: probe identity supplies genomic location and probe density controls granularity. Segmentation then compresses noisy locus values into candidate regions with interpretable boundaries.

Abstract Reasoning

Let true hybridizable copy amounts at locus \(i\) be \(C_{T,i}\) and \(C_{R,i}\). A simplified model is

\[ I_{T,i}=a_T h_i C_{T,i}+\epsilon_{T,i},\qquad I_{R,i}=a_R h_i C_{R,i}+\epsilon_{R,i}, \]

where \(h_i\) represents locus-specific hybridization efficiency and \(a_T,a_R\) label/channel effects. After normalization, the ratio reduces the shared \(h_i\) and estimates \(C_{T,i}/C_{R,i}\).

Spatially adjacent probes reporting a common shift increase evidence for a copy-number segment. Greater test-cell fraction or clonal amplitude predicts larger ratio departure. Mixed cell populations dilute the signal toward baseline.

A zero ratio does not prove identical genomes. It supports equal measured dosage at the assay's resolution; balanced rearrangements, sequence changes, allele origin, and sub-resolution variants can differ.

Knowledge Transfer

Literal transfer holds across chromosomal and array platforms because test/reference competition and locus-resolved ratio remain invariant. Cancer, prenatal, and constitutional contexts change samples and interpretation, not the comparator architecture.

The portable residue is ratio-based comparative measurement: expose target and reference to shared conditions and infer relative quantity from their signal quotient. Live prime:ratio supplies this core. CGH adds genomic DNA, hybridization, fluorophores, ordered loci, copy-number biology, and cytogenetic limitations.

Transfer becomes analogy for any comparison without competitive genomic hybridization.

Examples

Tumor amplification. Test tumor DNA produces a sustained positive log2 ratio across adjacent probes relative to normal reference DNA, supporting regional copy-number gain.

Constitutional deletion. A child's test DNA shows a negative segment across multiple probes on one chromosome arm, consistent with relative deletion and routed to clinical interpretation.

Conventional CGH. Differently labeled tumor and normal DNA hybridize to normal metaphase chromosomes; a color-ratio shift along a chromosome locates a broad gain.

Array CGH. The same DNA pair hybridizes to thousands of mapped probes, resolving a smaller subchromosomal imbalance.^[3]

Negative—balanced translocation. All DNA remains in equal dosage but changes location. The ratio profile can remain neutral.

Negative—single-nucleotide variant. One base changes without copy-number difference and is below the method's identity.

Boundary—reference deletion. Elevated test/reference ratio can arise because the reference has fewer copies; reference choice is part of interpretation.

Structural Tensions

T1: Genome-wide breadth versus variant specificity. CGH surveys dosage broadly but does not characterize every sequence or rearrangement.

T2: Relative control versus absolute ambiguity. Ratio cancels shared effects while tying interpretation to reference and ploidy assumptions.

T3: Resolution versus noise and burden. Denser arrays localize smaller events but increase measurements, multiple-testing concerns, and uncertain findings.

T4: Sensitivity versus mixture dilution. Subclonal or mosaic events are biologically real yet produce weaker ratios.

T5: Competitive control versus dye bias. Co-hybridization shares conditions, but label channels introduce asymmetry requiring normalization or swaps.

T6: Detection versus interpretation. A reproducible dosage segment can still be benign, pathogenic, or uncertain.

Structural–Framed Character

CGH is strongly structural at the assay layer: paired genomes, differential labels, common substrate, local ratio, and copy-number inference form a repeatable chain.

It is framed at calibration and interpretation. Platform, reference genome, specimen mixture, ploidy, probe design, thresholds, and clinical context determine sensitivity and meaning. These do not turn the assay into another abstraction; they specify its operating conditions.

Structural Core vs. Domain Accent

The structural core is controlled ratio measurement: compare target with reference under shared transformation and map normalized departures.

The domain accent includes genomic DNA, copy number, fluorophore labeling, hybridization, metaphase chromosomes or arrays, locus order, CNVs, mosaicism, and balanced-rearrangement blindness. Without these, one has generic Ratio rather than CGH.

Instantiates / Related Primes

The minimal prospective placement is a strict composition/presupposes edge to live prime:ratio. The test-to-reference signal ratio is the measurement that turns two hybridization channels into relative copy-number evidence; removing it destroys CGH's comparative identity.

Measurement, comparison, normalization, and signal detection are related. Frozen domain_specific:radiation_hybrid_mapping is false coverage because marker-retention mapping does not implement the test/reference dosage ratio.

Relationships to Other Abstractions

Current abstraction Comparative Genomic Hybridization Domain-specific

Parents (1) — more general patterns this builds on

• Comparative Genomic Hybridization presupposes Ratio Prime

  The minimal prospective placement is a strict composition/presupposes edge to live prime:ratio.

Hierarchy path (1) — routes to 1 parentless root

• Comparative Genomic Hybridization → Ratio → Comparison → Self Checking

Neighborhood in Abstraction Space

Comparative Genomic Hybridization sits in a sparse region of the domain-specific corpus (89^th percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.

Family — Genomic Mapping & Sequence Assays (6 abstractions)

Nearest neighbors

• Radiation Hybrid Mapping — 0.85
• Fluorescence In Situ Hybridization — 0.79
• Surveyor Nuclease Assay — 0.78
• Epitope mapping — 0.78
• DNA Replication — 0.78

Computed from structural-signature embeddings · 2026-09-08

Not to Be Confused With

Array CGH: higher-resolution substrate variant within CGH.

Chromosomal microarray: clinical platform family that may include array CGH and SNP-array designs.

FISH: usually targeted locus visualization rather than genome-wide test/reference ratio profiling.

Karyotyping: cell-based chromosome morphology.

Radiation hybrid mapping: marker ordering by retention.

Sequencing: base-level read measurement with different capabilities.

Copy-number variation: biological finding, not the assay.

References

[1] Kallioniemi, Anne, et al. “Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors.” Science 258 (1992): 818–821. https://doi.org/10.1126/science.1359641. registry ↩a ↩b

[2] du Manoir, Stanislas, et al. “Detection of Complete and Partial Chromosome Gains and Losses by Comparative Genomic in Situ Hybridization.” Human Genetics 90 (1993): 590–610. https://doi.org/10.1007/BF00202476. registry ↩

[3] Pinkel, Daniel, et al. “High Resolution Analysis of DNA Copy Number Variation Using Comparative Genomic Hybridization to Microarrays.” Nature Genetics 20 (1998): 207–211. https://doi.org/10.1038/2524. registry ↩a ↩b

[4] Miller, David T., et al. “Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital Anomalies.” American Journal of Human Genetics 86 (2010): 749–764. https://doi.org/10.1016/j.ajhg.2010.04.006. registry ↩